title: Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
abstract: Proteasome inhibition is associated with substantial antitumor effects in preclinical models of multiple myeloma (MM) as well as in patients. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade(®), also called PS-341) in MM patients have shown limited activity when used as a single agent. This underscores the need to find new efficacious and less toxic proteasome inhibitors. Recently, carfilzomib was approved for the treatment of refractory/relapsed MM and several new agents have been introduced into the clinic, including marizomib and MLN9708, and trials investigating these second-generation proteasome inhibitors have demonstrated promising results. We have recently synthesized a novel proteasome inhibitor, BU-32, and tested its growth inhibitory effects in different human MM cells including RPMI8226, MM.1S, MM.1R, and U266. In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499) using an in vitro MM model. BU-32 exhibits strong cytotoxicity in a panel of MM cell lines--RPMI8226, MM1S, MM1R, and U266. In addition, we demonstrate by proteasome inhibition assay that BU-32 potently inhibits the chymotryptic- and caspase-like activities of the 26S proteasome. We further show from Annexin V-FITC binding studies that BU-32, like Bortezomib, induces apoptosis in a panel of MM cell lines but the effect is more pronounced with BU-32-treated cells. Invasion assay with the MM.1S cell line indicates that BU-32 inhibits the invasiveness of myeloma cells. Results from our studies using real-time PCR array analyses show that BU-32 effectively downregulates an array of angiogenesis and inflammatory markers. Our results suggest that BU-32 might be a potential chemotherapeutic agent with promising antitumor activity for the treatment of MM.
authors.affiliation: Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
authors.forename: Sudipa S
authors.initials: SS
authors.lastname: Roy
authors.forename: Nameer B
authors.initials: NB
authors.lastname: Kirma
authors.forename: Bindu
authors.initials: B
authors.lastname: Santhamma
authors.forename: Rajeshwar R
authors.initials: RR
authors.lastname: Tekmal
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Agyin
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D061945:Caspase Inhibitors / Q000494:pharmacology; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002918:Chymotrypsin / Q000037:antagonists & inhibitors / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*
chemical_list: D061945:Caspase Inhibitors; C547394:NSC D750499-S; D061988:Proteasome Inhibitors; D011720:Pyrazoles; D002918:Chymotrypsin; D020169:Caspases
references.citation: Blood. 2005 Jun 15;105(12):4784-91
references.pmid: 15731178
references.citation: Cancer Res. 2007 Mar 1;67(5):1918-26
references.pmid: 17332318
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1649-57
references.pmid: 18347166
references.citation: Leuk Lymphoma. 2008 Apr;49(4):677-89
references.pmid: 18398734
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3113-20
references.pmid: 16754936
references.citation: Cancer Invest. 2004;22(2):304-11
references.pmid: 15199612
references.citation: Blood. 2008 Feb 1;111(3):1654-64
references.pmid: 18006697
references.citation: Fertil Steril. 2008 Oct;90(4 Suppl):1487-95
references.pmid: 18163995
references.citation: Cancer Res. 2007 Feb 15;67(4):1783-92
references.pmid: 17308121
references.citation: Cancer Res. 2006 Jan 1;66(1):184-91
references.pmid: 16397231
references.citation: Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7156-61
references.pmid: 9207060
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 16):3-9; discussion 33
references.pmid: 15799238
references.citation: Nat Rev Cancer. 2004 May;4(5):349-60
references.pmid: 15122206
references.citation: Structure. 2006 Mar;14(3):451-6
references.pmid: 16531229
references.citation: Mol Cancer Ther. 2002 Dec;1(14):1243-53
references.pmid: 12516957
references.citation: Blood. 2012 Aug 2;120(5):947-59
references.pmid: 22645181
references.citation: Mol Hum Reprod. 2009 Oct;15(10):665-73
references.pmid: 19505996
references.citation: Breast Cancer Res. 2009;11(5):R74
references.pmid: 19821999
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:465-76
references.pmid: 15822185
references.citation: Cancer Res. 2007 Jul 1;67(13):6383-91
references.pmid: 17616698
references.citation: J Biol Chem. 2006 Mar 31;281(13):8582-90
references.pmid: 16455650
references.citation: Science. 1995 Apr 28;268(5210):533-9
references.pmid: 7725097
references.citation: Nature. 1995 Nov 23;378(6555):416-9
references.pmid: 7477383
references.citation: Mol Cell Biol. 2004 Nov;24(22):9695-704
references.pmid: 15509775
references.citation: Angew Chem Int Ed Engl. 2005 Sep 19;44(37):5944-67
references.pmid: 16142822
references.citation: Biochim Biophys Acta. 2004 Nov 29;1695(1-3):33-44
references.pmid: 15571807
references.citation: Mol Hum Reprod. 2008 May;14(5):301-7
references.pmid: 18359784
references.citation: Chem Biol. 2001 Aug;8(8):739-58
references.pmid: 11514224
references.citation: Blood. 2000 Apr 15;95(8):2630-6
references.pmid: 10753844
references.citation: Br J Pharmacol. 2003 Oct;140(4):595-610
references.pmid: 14504135
references.citation: Clin Cancer Res. 2001 Nov;7(11):3349-55
references.pmid: 11705847
references.citation: Hematology Am Soc Hematol Educ Program. 2011;2011:184-90
references.pmid: 22160032
references.citation: J Biol Chem. 1997 Oct 3;272(40):25200-9
references.pmid: 9312134
references.citation: Mol Oncol. 2008 Dec;2(4):317-26
references.pmid: 19383353
references.citation: Nat Methods. 2005 May;2(5):357-62
references.pmid: 15846363
references.citation: Blood. 2010 Dec 2;116(23):4906-15
references.pmid: 20805366
references.citation: Cancer Res. 2006 Jun 15;66(12):6379-86
references.pmid: 16778216
references.citation: Cancer Res. 2010 Mar 1;70(5):1970-80
references.pmid: 20160034
references.citation: Mol Cancer Ther. 2006 Dec;5(12):3042-51
references.pmid: 17148762
references.citation: Brain Res. 2001 May 18;901(1-2):38-46
references.pmid: 11368948
references.citation: J Clin Invest. 2006 Dec;116(12):3195-203
references.pmid: 17124531
references.citation: Curr Med Chem. 2011;18(34):5185-95
references.pmid: 22087819
references.citation: Blood. 2001 Jul 15;98(2):428-35
references.pmid: 11435313
references.citation: Biochem Soc Trans. 2007 Feb;35(Pt 1):12-7
references.pmid: 17212580
references.citation: Blood. 2005 Dec 1;106(12):3777-84
references.pmid: 16099887